0000000000210979

AUTHOR

Buzzetti R

showing 3 related works from this author

Polyphenol intake and cardiovascular risk factors in a population with type 2 diabetes: The TOSCA.IT study

2017

Background: The role of polyphenol intake on cardiovascular risk factors is little explored, particularly in people with diabetes. Aim: To evaluate the association between the intake of total polyphenols and polyphenol classes with the major cardiovascular risk factors in a population with type 2 diabetes. Methods: Dietary habits were investigated in 2573 males and females participants of the TOSCA.IT study. The European Prospective Investigation on Cancer and Nutrition (EPIC) questionnaire was used to assess dietary habits. In all participants, among others, we assessed anthropometry, plasma lipids, blood pressure, C-reactive protein and HbA1c following a standard protocol. The USDA and Ph…

Male0301 basic medicinePhysiologyType 2 diabetes030204 cardiovascular system & hematologyCritical Care and Intensive Care MedicineSettore MED/13 - Endocrinologiachemistry.chemical_compound0302 clinical medicineDietary polyphenolsFlavonoidsPhenolic acidsCardiovascular riskType 2 diabetesLOW-GRADE INFLAMMATIONBLOOD-PRESSUREDIETARY POLYPHENOLSDARK CHOCOLATEINSULIN SENSITIVITYRANDOMIZED-TRIALSDISEASEMETAANALYSISMETABOLISMCHOLESTEROLRisk FactorsSurveys and QuestionnairesHydroxybenzoatesProspective StudiesFood scienceCardiovascular risk; Dietary polyphenols; Flavonoids; Phenolic acids; Type 2 diabeteseducation.field_of_studyPhenolic acidNutrition and Dieteticsbiologyfood and beveragesType 2 diabetesDietary polyphenolMiddle AgedDietary polyphenols; Flavonoids; Phenolic acids; Cardiovascular risk; Type 2 diabetesEuropean Prospective Investigation into Cancer and NutritionDietary polyphenolsCardiovascular DiseasesFemalePhenolic acidsPopulationCardiovascular risk Dietary polyphenols Flavonoids Phenolic acids Type 2 diabetes03 medical and health sciencesDiabetes mellitusmedicineHumanseducationTriglyceridesAgedFlavonoids030109 nutrition & dieteticsDose-Response Relationship Drugbusiness.industryCholesterol HDLC-reactive proteinPolyphenolsCholesterol LDLAnthropometrymedicine.diseaseCardiovascular riskCardiovascular risk; Dietary polyphenols; Flavonoids; Phenolic acids; Type 2 diabetes; Nutrition and Dietetics; Critical Care and Intensive Care MedicineDietCross-Sectional StudiesNutrition AssessmentDiabetes Mellitus Type 2chemistryFlavonoidbiology.proteinGlycated hemoglobinbusinessBody mass index
researchProduct

Identification of Tyrosine Phosphatase 2(256-760) Construct as a New, Sensitive Marker for the Detection of Islet Autoimmunity in Type 2 Diabetic Pat…

2008

Abstract OBJECTIVE: The presence of autoantibodies to islet antigens GAD and/or tyrosine phosphatase 2 (IA-2) in type 2 diabetic patients (latent autoimmune diabetes in adults [LADA]) identifies subjects at high risk to develop insulin dependency. The aim of this study was to dissect humoral anti-IA-2 immune response in Caucasian LADA patients, identifying the most sensitive construct to evaluate IA-2 immunoreactivity and comparing LADA IA-2 epitope specificities to those found in type 1 diabetes. RESEARCH DESIGN AND METHODS: We analyzed 177 LADA and 978 type 2 diabetic patients with different disease duration, collected in a nationwide Italian survey, the Non-Insulin Requiring Autoimmune D…

diabetesSettore MED/13 - Endocrinologia
researchProduct

Liraglutide and Renal Outcomes in Type 2 Diabetes.

2017

BACKGROUND: In a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patients with type 2 diabetes and high cardiovascular risk who were receiving usual care, we found that liraglutide resulted in lower risks of the primary end point (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) and death. However, the long-term effects of liraglutide on renal outcomes in patients with type 2 diabetes are unknown. METHODS: We report the prespecified secondary renal outcomes of that randomized, controlled trial in which patients were assigned to receive liraglutide or placebo. The secondary renal outcome was a co…

MaleSettore MED/09 - Medicina InternaAcute Kidney Injury; Aged; Albuminuria; Creatinine; Diabetes Mellitus Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Intention to Treat Analysis; Kidney Failure Chronic; Liraglutide; Male; Middle AgedType 2 diabetes030204 cardiovascular system & hematologyurologic and male genital diseasesGLOMERULAR-FILTRATION-RATEKIDNEY-FUNCTIONDISEASElaw.inventionKidney Failurechemistry.chemical_compound0302 clinical medicineRandomized controlled trialGlucagon-Like Peptide 1lawMedicineDiabetic NephropathiesHypoglycemic Agents.Settore MED/49 - Scienze Tecniche Dietetiche ApplicateChronicRISKKidneyAcute kidney injury11 Medical And Health SciencesGeneral MedicineAcute Kidney InjuryMiddle AgedIntention to Treat Analysismedicine.anatomical_structureCreatinineTRIALFemaleliraglutide randomized controlled trial type 2 diabetes renal outcomesLife Sciences & BiomedicineType 2Glomerular Filtration Ratemedicine.drugmedicine.medical_specialtyRenal function030209 endocrinology & metabolismCARDIOVASCULAR OUTCOMESFollow-Up Studie03 medical and health sciencesMedicine General & InternalDouble-Blind MethodGeneral & Internal MedicineDiabetes mellitusInternal medicineDiabetes MellitusAlbuminuriaHumansHypoglycemic AgentsIntensive care medicineAgedCreatinineScience & Technologybusiness.industryLiraglutideMORTALITYLiraglutidemedicine.diseaseINTENSIVE GLUCOSE CONTROLINDIVIDUALSDiabetes Mellitus Type 2chemistryDiabetic NephropathieKidney Failure ChronicLEADER Steering Committee and InvestigatorsbusinessFollow-Up Studies
researchProduct